ClinicalTrials.gg
Not yet recruitingNCT07665684SONICUpdated Jun 24, 2026

Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer

A Phase 1/2 interventional study of Samuraciclib + Gemcitabine & Nab-Paclitaxel in Pancreas Ductal Adenocarcinoma, Pancreas Cancer, Metastatic and Pancreatic Adenocarcinoma Metastatic, sponsored by University Health Network, Toronto. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by University Health Network, Toronto · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
67
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 370 studies testing gemcitabine in Pancreatic Neoplasms — 30 open to participants now, 45 under way, 5 of them phase 3. Gemcitabine · Pancreatic Neoplasms.

Planned enrollment
100th of 353
67 · median 37
Started
2026
with 6 others
Phase 1/2
39 of 370
4 open now
Primary completion
2029-05
later than 44 of 44 live
Registered
368th of 370
by date

Among the 370 studies testing gemcitabine in Pancreatic Neoplasms, this one is the 100th largest by planned enrollment of the 353 interventional ones that give a count, is one of 7 that started in 2026, is one of 39 in phase 1/2, reaches primary completion later than 44 of the 44 other live ones, and was the 368th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

30 of the 370 studies testing gemcitabine in Pancreatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

25 more — sign in →

By country, each count listing its studies:

All 30 open studies →

About gemcitabine

Gemcitabine: first FDA approval 1996 (GEMZAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 370 studies testing gemcitabine in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to find the highest dose of a drug, samuraciclib, that can be given with standard of care chemotherapy (gemcitabine and nab-paclitaxel) without causing very severe side effects. This is done by starting at a dose lower than the one that is used when samuraciclib is taken by itself without chemotherapy. The main question it aims to answer is:

  • For patients with newly diagnosed metastatic pancreatic cancer, what is the safety and tolerability of samuraciclib with gemcitabine/nab-paclitaxel?

Participants will:

  • Undergo a tumor biopsy.
  • Be treated with samuraciclib in combination with their standard of care chemotherapy (gemcitabine/nab-paclitaxel).
  • Donate research blood samples.
03

Conditions studied

  • Pancreas Ductal Adenocarcinoma
  • Pancreas Cancer, Metastatic
  • Pancreatic Adenocarcinoma Metastatic
  • Adenosquamous Carcinoma of the Pancreas
  • Mucinous Adenocarcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years at the time of screening.
  2. Written and any locally required authorization (eg, data privacy) obtained from the patient prior to performing any protocol-related procedures, including screening evaluations.
  3. (ECOG) performance status of 0 or 1 at the time of screening.
  4. Must have ≥ 12 weeks at the time of screening.
  5. or cytologically confirmed PDAC: Eligible histological variants include: mucinous adenocarcinoma, independent cell adenocarcinoma, adenosquamous carcinoma, adenocarcinoma not otherwise specified (NOS).
  6. Dose Escalation: All patients with PDAC will be permitted to enrol.
  7. Dose Expansion: Patients with metastatic basal-like PDAC will be permitted to enrol, based on the PurIST assay or by transcriptomic sequencing. Patients will be permitted to start no more than one cycle of gemcitabine/nab-paclitaxel while waiting for transcriptional subtype results in the dose expansion cohort.
  8. Radiographic evidence of metastatic disease that is measurable per 1.1.
  9. Adequate organ and marrow function within 28 days prior to dosing on Day 1.
  10. Adequate liver function ( ≤2.5 times the institutional , total ≤2 times the institutional upper limit of normal) at the baseline visit. Patients are permitted to enroll with biliary obstruction, as long as they undergo appropriate biliary decompression (can be done at the same time as endoscopic ultrasound-guided fine-needle (EUS-FNB)) and hepatic parameters have improved at time of baseline visit.
  11. Patients must have either de novo metastatic disease or recurrence >6 months after completion of or adjuvant intent systemic therapy.
  12. Patients must have recovered to ≤ Grade 1 in terms of toxicity from prior treatments at the time of enrollment (excluding neuropathy which can be ≤ Grade 2, and alopecia)
  13. Patients must be able to take oral medications.
  14. Females of who are sexually active with a nonsterilized male partner must use at least one highly effective method of from screening to 180 days after the final dose of study treatment. It is strongly recommended for the male partner of a female patient to also use male condom plus spermicide throughout this period. Cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.
  15. Nonsterilized male patients who are sexually active with a female partner of childbearing potential must use a male condom with spermicide from screening to 180 days after receipt of the final dose of study treatment. It is strongly recommended for the female partner of a male patient to also use a highly effective method of contraception throughout this period. In addition, male patients must refrain from sperm donation while on study and for 180 days after the final dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  1. Participants receiving any other study agents concurrently with the study drugs.
  2. Known homologous recombination deficient pancreatic cancer, including germline or somatic BRCA1/2 or PALB2 mutations
  3. Concurrent enrolment in another therapeutic clinical study. Enrolment in observational or supportive care studies will be allowed.
  4. History of a malabsorption syndrome or uncontrolled nausea, vomiting, or diarrhea that may interfere with the absorption of oral study medication in the opinion of the investigator.
  5. Patients with a history of Grade 3 or greater thromboembolic events in the prior 3 months to the scheduled first dose of study treatment or thromboembolic event of any grade with ongoing symptoms.
  6. Patients with prior history of myocardial infarction, , congestive heart failure ≥ Class 3 based on Functional Classification or stroke within the past 3 months prior to the scheduled first dose of study treatment.
  7. Known active hepatitis infection, positive virus (HCV) antibody, virus (HBV) surface antigen (HBsAg) or HBV core antibody (anti-HBc), at screening. Participants with a past or resolved HBV infection (defined as the presence of anti HBc and absence of HBsAg) are eligible. Participants positive for HCV antibody are eligible only if polymerase chain reaction is negative for HCV RNA.
  8. Known to have tested positive for (HIV) (positive HIV 1/2 antibodies) or active tuberculosis infection (clinical evaluation that may include clinical history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).
  9. Other invasive within 2 years. Non-invasive malignancies (ie, cervical carcinoma in situ, in situ prostate cancer, non-melanomatous carcinoma of the skin, ductal carcinoma in situ of the breast that has been surgically cured) are excluded from this definition. Malignancy treated with curative intent and with no known active disease ≥2 years before the first dose of study treatment and of low potential risk for recurrence are permitted.
  10. Known allergy or to product formulations.
  11. Active grade 3 or greater edema (eg, peripheral, pulmonary).
  12. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written .
  13. Participants with known untreated are excluded. Patients with a history of brain metastases are permitted to enroll if they have been treated and have been stable for a minimum of one month on imaging. Participants must be off all at the time of enrolment.
  14. Major surgery (as defined by the investigator) within 28 days prior to scheduled first dose of study treatment or still recovering from prior surgery. Local procedures (eg, placement of a systemic port, core needle , etc) are allowed, without needing to wait for the 28 day recovery period.
  15. Females who are pregnant, lactating, or intend to become pregnant during their participation in the study.
  16. Any condition that, in the opinion of the investigator, would interfere with safe administration or evaluation of the investigational products or interpretation of patient safety or study results.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
67 participants (estimated)

Study arms

  • Experimental
    Samuraciclib + GnP

    Samuraciclib + Standard of Care Chemotherapy (Gemcitabine \& Nab-Paclitaxel)

    Drug: Samuraciclib + Gemcitabine & Nab-Paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Frequencies of adverse events (AEs), as graded by CTCAE v6.0 and reported by dose level

    Time frame: From date of enrollment to date off treatment, assessed up to 24 months

  2. Percentages of adverse events (AEs), as graded by CTCAE v6.0 and reported by dose level

    Time frame: From date of enrollment to date off treatment, assessed up to 24 months

  3. Frequencies of dose-limiting toxicities reported by dose level

    Time frame: From date of enrollment to date off treatment, assessed up to 24 months

  4. Percentages of dose-limiting toxicities reported by dose level

    Time frame: From date of enrollment to date off treatment, assessed up to 24 months

  5. Maximum tolerated dose, defined as the highest dose level where a dose-limiting toxicity occurs within at most one out of six patients treated

    Time frame: From date of enrollment to date off treatment, assessed up to 24 months

  6. Recommended phase II dose (RP2D)

    The RP2D will be selected based on the evaluation of dose-limiting toxicities and adverse events measured using CTCAE v6.0.

    Time frame: From date of enrollment to date off treatment, assessed up to 24 months

Secondary outcomes

  1. Objective response rate (ORR)

    Defined as the proportion of participants who achieve a Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 best overall response of confirmed complete response (CR) or confirmed partial response (PR)

    Time frame: From date of enrollment to date off treatment, assessed up to 24 months

  2. Progression-free survival (PFS)

    Defined as the duration of time from start of treatment to time of disease recurrence/progression (PD) or death from any cause, whichever occurs first.

    Time frame: From date of enrollment to date of first progression or death, assessed up to 24 months

  3. Overall survival (OS)

    Defined as the duration of time from time of diagnosis to death.

    Time frame: From date of enrollment to date of death, assessed up to 24 months

  4. Duration of overall response (DOR)

    Defined as the duration of time from when measurement criteria are met for CR or PR (whichever is first recorded) until the date that recurrent/progressive disease (PD) is objectively documented (taking as reference for PD the smallest measurements recorded since the treatment started).

    Time frame: From date of enrollment to date of first progression, assessed up to 24 months

Other outcomes

  1. Comparison of PDAC transcriptional subtype (basal vs classical) between baseline and 8 week sample

    Evaluate translational biomarkers related to CDK7 inhibition with samuraciclib by comparing tissue and blood samples at pre-treatment and at 8 weeks.

    Time frame: From enrollment to 8 weeks on treatment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for May 2029, 34 months later.

Of 95 non-industry phase 1/2 interventional studies under Pancreatic Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 95. This study's planned 34 months is below that.

Counting every sponsor, half of 209 studies reached it within 51 months; a quarter within 36 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2026
First posted
Jun 24, 2026
StartEst.
Jul 2026
Primary completionEst.
May 2029
CompletionEst.
May 2030
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07665684
Responsible party
Sponsor
First posted
Jun 24, 2026
Start date
Jul 2026 (estimated)
Primary completion
May 2029 (estimated)
Completion
May 2030 (estimated)
Last update
Jun 24, 2026

Study contacts

Erica Tsang, MD
Contact
Erica.Tsang@uhn.ca
4169462000

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Samuraciclib · Gemcitabine · Albumin-Bound Paclitaxel

Start the discussion